Giles Platford/LinkedIn
Dec 12, 2025, 09:34
Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
Giles Platford, President, Plasma-Derived Therapies Business Unit at Takeda and Chair of the Global Executive Board at PPTA, shared on LinkedIn:
”Plasma-derived therapies are often the only effective treatment for patients with certain rare and complex, chronic conditions.
One case in point is infant botulism: in partnership with the California Department of Public Health, on a non-profit basis, Takeda produces the only FDA-approved treatment for this condition, Baby Big.
The recent outbreak of infant botulism in the U.S. has put a fine point on the importance of this therapy.
Learn more in this story from The Independent”
Stay updated with Hemostasis Today.
-
Jun 21, 2026, 11:50Khalil Ahmad: The Incredible Journey of a Red Blood Cell – A Lifelong Mission of Oxygen Delivery
-
Jun 21, 2026, 08:44Patient Experience Sheds Light on Complexities of Antithrombotic Care in APS – APS Foundation of America
-
Jun 21, 2026, 08:04Phil Ambery: Next-Generation Endothelin Therapeutics Renew Interest in a Proven Pathway
-
Jun 21, 2026, 07:50Pallavi Madhiraju: Evategrel Shows Promise for Rapid and Consistent Platelet Inhibition
-
Jun 21, 2026, 07:39Heghine Khachatryan: Emerging Evidence Links NET Formation to Thrombosis and Disease Progression in Gynecologic Malignancies
-
Jun 21, 2026, 07:24Seema Dawood: The Power of Blood Smear Confirmation in Detecting Immature Granulocytes
-
Jun 21, 2026, 05:32Flora Peyvandi: Characterizing Acquired VWD Through a Large Patient Cohort
-
Jun 21, 2026, 05:23Mohammed Alo: The Gap Between Nattokinase Marketing and Evidence
-
Jun 21, 2026, 05:11Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar N63